Replies to post #38939 on Ariad Pharmaceuticals Inc fka ARIA

[grandma_of_jbraika]

Doctors know more about Iclusig than the FDA. Those who conduct the clinical trials of Iclusig and treat the patients in person know about the safety/toxicity more than anybody else. They believe Ponatinib is well tolerated and Adverse Events are manageable.

The doctors obviously disagree with the FDA as 23 leukemia specialists and 3 patient advocacy groups sent the FDA a letter saying they were concerned right after the FDA withdrew the life-saving drug Iclusig.
******
Doctors: Ponatinib is a good drug. We don’t want it to be killed and not given to patients.

“Without this medication, they won’t have long to live. My patients are panicked. I have patients right now who are benefiting from this medication with very few side effects.” said Dr. Brian Druker, the director of the Knight Cancer Institute at Oregon Health and Science University.

“What we don’t want to have happen is for a good drug, ponatinib, to be killed and not given to patients,” said Dr. Javid Moslehi, a co-director of the cardio-oncology program at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston.

Source: Doctors Fear Losing Leukemia Drug Deemed Risky,The New York Time, November 1, 2013

The doctors will tell more truth about the Efficacy and Safety of Iclusig at the 55th ASH, December 7-10, 2013. They believe Ponatinib is well tolerated and Adverse Events are manageable.

Dr. Javid Moslehi said in an interview that if, for instance, the problems were known to occur because of excessive blood clotting from a cancer drug, then patients could also be given another medication to prevent clots. Or, if the cancer drug were causing plaque to build up in the arteries, patients might be given a statin to try to prevent it.

“What we don’t want to have happen is for a good drug, ponatinib, to be killed and not given to patients,” Dr. Moslehi said.